User profiles for D. Eleftheriou

Despina Eleftheriou

Verified email at ucl.ac.uk
Cited by 5487

Management of Kawasaki disease

D Eleftheriou, M Levin, D Shingadia, R Tulloh… - Archives of disease in …, 2014 - adc.bmj.com
Kawasaki disease (KD) is an acute self-limiting inflammatory disorder, associated with
vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries. In …

European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease–the SHARE initiative

N de Graeff, N Groot, S Ozen, D Eleftheriou… - …, 2019 - academic.oup.com
… : expert opinion; SoR: strength of recommendation; A: based on level 1 evidence; B: based
on level 2 or extrapolated from level 1; C: based on level 3 or extrapolated from level 1 or 2; D

Medium-size-vessel vasculitis

MJ Dillon, D Eleftheriou, PA Brogan - Pediatric Nephrology, 2010 - Springer
Medium-size-artery vasculitides do occur in childhood and manifest, in the main, as polyarteritis
nodosa (PAN), cutaneous PAN and Kawasaki disease. Of these, PAN is the most serious…

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

…, K Deiva, E Andersen, MR Eyre, D Eleftheriou… - Neurology, 2014 - AAN Enterprises
… PhD Fellowship for Dr D Eleftheriou. 1/8/09-31/7/2012 5. Arthritis Research UK. … Eleftheriou
has received funding from Arthritis Research UK. P. Brogan has received consultancy fees …

Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles

Y Hong, D Eleftheriou, AAK Hussain… - Journal of the …, 2012 - journals.lww.com
The mechanisms by which anti-neutrophil cytoplasmic antibodies (ANCAs) may contribute to
the pathogenesis of ANCA-associated vasculitis are not well understood. In this study, both …

The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of …

…, RC Dale, KL Durrant, D Eleftheriou… - Arthritis & …, 2022 - Wiley Online Library
… The strength of each statement ranged from A (directly based on level I evidence) to D (directly
based on level IV evidence or extrapolated recommendations from level I, II, or III …

Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases

…, K Gilmour, NJ Klein, D Eleftheriou… - Arthritis & …, 2016 - Wiley Online Library
… Renovascular involvement was present in 3 subjects (subjects D, E, and F), with renal
arterial aneurysms and other features of medium vessel vasculitis demonstrated on catheter …

Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)

…, CA Wallace, N Wilkinson, D Eleftheriou… - Annals of the …, 2013 - ard.bmj.com
Background Rare chronic childhood vasculitides lack a reliable disease activity assessment
tool. With emerging new treatment modalities such a tool has become increasingly essential …

Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1

…, SM Gomes, N Klein, D Eleftheriou… - Journal of Experimental …, 2017 - rupress.org
… 5 D), suggesting that the phagocytic defect may not affect all phagocytic cell types to the same
extent… 3 D) similar to those we observed in the patient moDCs (Fig.3B). We then studied co-…

Systemic polyarteritis nodosa in the young: a single‐center experience over thirty‐two years

D Eleftheriou, MJ Dillon, K Tullus… - Arthritis & …, 2013 - Wiley Online Library
Objective Polyarteritis nodosa (PAN) is a rare disease of childhood. The aims of this study
were to describe the clinical features, treatment, and outcome of systemic childhood PAN and …